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Abstract
Head and neck squamous cell carcinoma (HNSCC) is characterized by significant genomic instability that could lead to
clonal diversity. Intratumor clonal heterogeneity has been proposed as a major attribute underlying tumor evolution,
progression, and resistance to chemotherapy and radiation. Understanding genetic heterogeneity could lead to treat-
ments specific to resistant andmetastatic tumor cells. To characterize the degree of intratumor genetic heterogeneity
within a single tumor,we performedwhole-genomesequencing on three separate regions of an human papillomavirus
(HPV)-positive oropharyngeal squamous cell carcinoma and two separate regions from one corresponding cervical
lymph nodemetastasis. This approach achieved coverage of approximately 97.9% of the genome across all samples.
In total, 5701 somatic pointmutations (SPMs) and4347 small somatic insertionsanddeletions (indels)were detected in
at least one sample. Ninety-two percent of SPMs and 77%of indelswere validated in a second set of samples adjacent
to the discovery set. All five tumor samples shared 41%of SPMs, 57%of the 1805 geneswith SPMs, and 34 of 55 cancer
genes. The distribution of SPMs allowed phylogenetic reconstruction of this tumor’s evolutionary pathway and showed
that the metastatic samples arose as a late event. The degree of intratumor heterogeneity showed that a single biopsy
may not represent the entiremutational landscape of HNSCC tumors. This approachmay be used to further characterize
intratumor heterogeneity inmore patients, and their sample-to-sample variations could reveal the evolutionary process of
cancer cells, facilitate our understanding of tumorigenesis, and enable the development of novel targeted therapies.
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Introduction
For patients with head and neck squamous cell carcinoma (HNSCC),
a major challenge that contributes to treatment failures is the emer-
gence of chemotherapy and radiation resistance after an initial re-
sponse. A major factor contributing to such treatment resistance is
intratumor genomic heterogeneity [1]. Heterogeneous cancer cell
populations with different genetic mutations are typically retained
within tumors [1,2]. Recent studies using whole-exome sequencing
of multiple tumor samples from patients with pancreatic cancer and
renal cell carcinoma have demonstrated significant intratumor hetero-
geneity and clonal evolution, with metastatic potential possibly exist-
ing only in a small proportion of tumor cells [3,4]. These studies also
suggest that metastatic clones may develop late in the course of tumor
progression. Thus, understanding the genomic heterogeneity of tumors
and the clonal events that lead to metastasis is paramount to eradicate
all tumor clones and successfully treat HNSCC.
Previous studies have identified a large number of genetic muta-
tions found in single samples from patients with HNSCC [5,6]. The
recent adoption of next-generation sequencing technologies has
greatly expanded our ability to identify the full extent of genomic
instability and heterogeneity; however, an analysis of whole-genome
intratumor heterogeneity within HNSCC tumors, particularly at the
individual nucleotide level, has not been performed. Here, we per-
formed one such study to demonstrate the feasibility of obtaining
multiple intratumor samples and the application of next-generation
sequencing technologies to determine the presence of intratumor
heterogeneity in HNSCC. By obtaining physically separated samples
from a primary tumor and corresponding metastatic lymph node, we
detected widespread intratumor heterogeneity, which we used to recon-
struct the evolutionary path of tumor clones.
Materials and Methods
Sample Collection
Research involving collection of tissue from human subjects was
approved by the institutional review board at the Fred Hutchinson
Cancer Research Center, and informed consent was obtained from
the patient before participation. All tumor tissue specimens were col-
lected from a 71-year-old male patient with stage IV, T2N2a, human
papillomavirus (HPV)-positive oropharyngeal squamous cell carci-
noma (OSCC) at the time of diagnostic direct laryngoscopy and cer-
vical lymphadenectomy. The tumor measured 2.6 × 2.3 × 3.5 cm,
whereas the metastatic lymph node measured 3.3 × 2.3 × 2.9 cm.
Three separate cup biopsies (∼4-mm punch), denoted as T1, T2,
and T3, were obtained from separate sections approximately 1 cm
apart from each other. In a similar fashion, two spatially separated
samples were obtained from one metastatic lymph node, denoted as
M1 and M2. The tissue specimens were snap frozen in the operating
theater and stored in liquid nitrogen until use. The HPV status was
ascertained by testing one of the samples for presence of E6 sequence
by polymerase chain reaction (PCR) through a well-established method
published by Sotlar et al. [7]. In addition, as part of standard of care, a
tumor sample was sent for diagnosis and p16 immunohistochemistry
(IHC) by the Department of Pathology at the University ofWashington
(Seattle, WA); uniformly positive p16 staining was confirmed.
DNA Purification
Tissue specimens were embedded in Tissue-Tek OCT compound
(Sakura Finetek USA, Torrance, CA), sectioned, and prepared as pre-
viously described [8]. One section from each sample was stained with
hematoxylin and eosin, and OSCC tumor cells were outlined by our
study pathologist. Adjacent sections were then macrodissected under
microscopic visualization to enrich for >80% tumor epithelial cells.
DNA was extracted from the purified tumor cells using a DNeasy
Blood & Tissue Kit (Qiagen, Valencia, CA) following the manufac-
turer’s instructions. Quantity and quality of the purified DNA were
assessed with an ND-1000 spectrophotometer (Thermo Fisher Sci-
entific, Rockford, IL). A DNA sample was also extracted from the
patient’s peripheral blood (denoted as “N”) using an ArchivePure
DNA Blood Kit (5 PRIME Inc, Gaithersburg, MD) following the
manufacturer’s instructions. DNA was additionally isolated in the
same fashion from adjacent sections of each tissue specimen as a
validation batch. Batch “a” DNA served as the discovery set of
samples, which included T1a, T2a, T3a, M1a, M2a, and blood
DNA Na. Batch “b” DNA served as validation samples to confirm
the discoveries in batch “a,” which included T1b, T2b, T3b, M1b,
M2b, and blood DNA Nb (Na and Nb were from the same DNA
prep). All samples yielded sufficient DNA for sequencing with an
OD260/280 ratio between 1.8 and 2.0.
Whole-Genome DNA Sequencing
Whole-genome sequencing (WGS) was conducted by Illumina
(San Diego, CA) using HiSeq 2000 technology. After sequencing batch
“b” samples, we chose a second round of sequencing, using the adjacent
samples named batch “b” to assess if somatic mutations were largely
consistent. Batch “a” and batch “b” samples were sequenced 6 months
apart. More than 1 billion paired-end reads of 100 bp each in length
were generated for each DNA sample. Batch “a” was sequenced in June
2011. Batch “b” samples were sequenced in January 2012, after
Illumina made improvements in sequencing technology and calling
algorithms (Illumina, personal communication). After aligning and
assembling the short-read sequences to human genome reference
sequence National Center for Biotechnology Information (NCBI,
Bethesda, MD) Build 37/hg19, Illumina provided initial variant call-
ings using CASAVA 1.8 for batch “a” samples and CASAVA version
1.9 for batch “b” samples, with all computational parameters per rec-
ommendation. The primary difference between these two versions of
CASAVA pertains to detection of large structural mutations, such as
copy number variations or structure variations, but not detection of
single nucleotide polymorphisms (SNPs) or small insertions/deletions
(indels). To mitigate this issue and for analytic consistency between the
two batches of samples, we primarily focused on small mutations
(SNPs/indels) for this study. Using either HPV16 or HPV18 genome
sequence as a reference, we used Burrows-Wheeler Aligner software
(Wellcome Trust Sanger Institute, Cambridge, United Kingdom) [9]
to align the short-read sequences of ourWGS samples (both tumor and
blood) to the HPV genome and look for integration sites.
Somatic Mutation Detection
Using germline DNA samples from blood as references (sequenced
in both batches and denoted as Na and Nb), we identified somatic
point mutations (SPMs) and somatic indels in each tumor specimen.
To minimize false-positive discovery rate, we applied a set of stringent
and relatively conservative criteria on the basis of quality scores of
individual reads, read depth, and variant calling confidence. (For
details, see Supplemental Methods section.) In addition, we excluded
mutations that have been identified in public databases, including the
NCBI single nucleotide polymorphism database (dbSNP) and the
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1000 Genomes Project (The EMBL-European Bioinformatics Institute,
Cambridge, United Kingdom), on the basis of the assumption that the
mutations in these databases are less likely to represent somatic, cancer-
causing mutations because they were mostly discovered from germline
DNA samples.
To test for reproducibility, we used batch “b” samples to validate
the somatic mutations detected in batch “a” samples. By study design,
each sample in batch “b” corresponded to the next physically adjacent
sample in batch “a.” Thereby, we evaluated the validation rate as the
percentage of somatic mutations detected in each (or any) batch “a”
sample that were also detected in the corresponding (or any) batch
“b” sample.
A Venn diagram plot showing shared and unique genes with iden-
tified SPMs among all batch “a” samples was made using an R code
from https://stat.ethz.ch/pipermail/bioconductor/2007-October/
019703.html.
Annotating Mutations
We annotated somatic mutations on the basis of RefSeq gene hg19
using ANNOVAR (University of Pennsylvania, Philadelphia, PA) [10].
Firstly, somatic mutations were annotated against 488 cancer-associated
genes that have mutations causally implicated in cancer (http://www.
sanger.ac.uk/genetics/CGP/Census) on the basis of whether their
locations were in the gene-coding, intronic, downstream, upstream,
or intergenic regions. The cancer-associated genes implicated in our
patient with OSCC were examined for their functions using Ingenuity
Pathway Analysis (version 16542223; Ingenuity Systems Inc, Redwood
City, CA) and heterogeneity among tumor samples. Secondly, possible
functions such as stop-gain, synonymous/nonsynonymous were anno-
tated whenever possible, particularly for those mutations in gene-
coding regions.
Cancer Genome Evolution
To explore the evolutionary history of this tumor, we focused on
the variations within 1-kb flanking coding regions of genes contain-
ing somatic mutations [11]. For each pair of tumor samples, we cal-
culated their distance as the number of nonshared mutational genes.
On the basis of this distance, a coalescent tree was then constructed
using the neighbor-joining method [12] in MATLAB version 2011b
(The MathWorks, Inc, Natick, MA). On the basis of the set of
somatic mutations, we estimated the chronological time for the evo-
lution of the sampled tumor cell populations on the basis of previous
estimations of mutation frequency as described by Yachida et al. [4].
Major phases of tumor evolution were estimated as described in
Supplemental Methods section. Briefly, we set the time from tumor
initialization to the parental clone as the time to accumulate the
number of somatic mutations shared in all 10 tumor samples. The
average time from the parental clone to subclones was calculated as
the time to accumulate the average number of mutations in each
primary tumor but not in the parental clone. The average time to
develop metastasis was calculated as the time to accumulate the
average number of mutations in each metastasis but neither in the
primary tumor nor in the parental clone. To evaluate the signifi-
cance of a coalescent tree, we performed “bootstrap sampling,” in
which a randomly selected subset (80%) of genes containing at least
one SPM in one tumor sample were used to plot the coalescent tree.
We also performed “jackknife sampling” to evaluate the stability of
the coalescent tree. Specifically, we left one sample out at a time and
performed a coalescent analysis on the remaining samples. Then, we
evaluated whether the coalescent tree from each jackknife sample
was consistent to the complete tree.
Results
Sequencing Characteristics
Sequencing statistics for both batches of DNA samples were
summarized in Table 1. The sequence coverage of the six batch “a”
samples was comparable, with a mean depth of 44.7X (range = 41.7-
48.0) and coverage of 97.9%. Using the cutoff of quality scoreQ≥ 20,
approximately 3.6 million SNPs and approximately 600 thousand
indels were detected (Table 1). The coverage in batch “b” samples
was similar to that of batch “a” samples, but mean depth was lower
at 36.8X (range = 34.9-39.3). On average, the number of SNPs and
indels detected in batch “b” samples was 32,860 (0.9%) and 34,246
(5%), lower than that in the corresponding samples in batch “a.” In
addition, the concordance between the genotypes of SNPs detected
by sequencing versus Illumina Quad SNP array was slightly lower for
samples in batch “b” (99.3%) compared to that in batch “a” (99.9%)
samples. Other sequencing characteristics were comparable between
all tumor samples both within or between the batches. For example,
the ratio of transition and transversion type of mutations was consistent
at 2.06, and greater than 93% of SNPs detected in each tumor was
reported in dbSNP version 131. Interestingly, despite detection of
HPV E6 sequences by PCR and uniformly positive p16 staining by
IHC, we did not observe alignment of short-read sequences from our
WGS data (either from tumor or blood) with sequences from HPV 16
or 18 reference genomes.
Somatic Point Mutations
In total, 5701 SPMs were detected in at least one of the five pri-
mary tumor or metastatic samples in the discovery set (batch “a”). Of
these, 5236 were confirmed in at least one tumor/metastatic sample
in the validation set (batch “b”) for an overall validation rate of 92%.
The number of SPMs in a single sample varied from 3228 to 4043,
around 85% of which could be confirmed in the corresponding
physically adjacent sample in the validation set (Table 2). Further-
more, the genomic distribution of SPMs for samples from the two
batches were largely concordant, as shown by comparing the number
of SPMs in sliding windows of size 500 kb (Figure W1A). Among
the 10 samples in both batches, we detected a total of 6440 SPMs.
Examining the distributions of SPMs, we found that the two tran-
sition types of mutations C > T/G > A and A > G/T > C were most
frequent at 40.5% and 18.9%, respectively, over the entire genome
(Figure 1A). However, the C > T/G > A mutations were much more
enriched in coding regions, with a frequency of 63.5%, whereas A >
G/T > C mutations were at 4.63% (Figure 1B). This distribution
was reminiscent of the SPM pattern observed in malignant melanoma
[13]. The distribution pattern was largely consistent across the five
samples in batch “a,” with no apparent differences between tumor
and metastatic samples.
Of the SPMs detected in the discovery set, 1153 were only in the
primary tumors, and 792 were only in the metastatic samples. More-
over, the primary tumors were more heterogeneous than the meta-
static ones, with 51.7% and 76.7% shared SPMs, respectively. Overall,
41% SPMs were shared among all five tumors (primary or metastatic).
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Small Somatic Indels
In this study, somatic indels were determined as insertions or dele-
tions up to 300 bp in length. Following a set of stringent criteria (see
Materials and Methods section), we identified a total of 4347 somatic
indels in at least one of the five tumor samples in the discovery set (batch
“a”). Of these, 3368 were confirmed in at least one tumor/metastatic
sample in the validation set (batch “b”) for an overall validation rate
of 77% (Table 2). The average number of somatic indels in a single sam-
ple was 3170. The genomic distributions of somatic indels were largely
concordant, similar to the SPMs (Figure W1B). Among the 10 samples
in both batches, there were a total of 4638 somatic indels detected.
Similar to SPMs, the number of somatic indels specific to pri-
mary tumors was greater than the number specific to metastatic
samples (613 and 329, respectively). The primary tumors shared
59% of somatic indels, whereas the metastatic samples shared
68%. Overall, 46% somatic indels were shared among all five tumors
(primary or metastatic).
Annotations of Mutations
As shown in Table 3, of the entire 6440 SPMs in the two batches
of samples, only 61 (<1%) SPMs resided in the coding region.
Among these, 41 were nonsynonymous; 16 were synonymous; three
SPMs could not be annotated due to errors in the gene structure def-
inition in the database; and one represented a stop-gain SPM in gene
poly(A) polymerase beta (testis specific) (PAPOLB) at chr7:4900509,
which leads to the creation of stop codon at the site. Of SPMs in
the noncoding region, 17 SPMs were in the exonic region of non-
coding RNA, and 1 SPM was located in an intron 1 bp from a splic-
ing junction (Table W1). The majority (68.7%) of SPMs were in
intergenic regions, which were more than 1 kb away from the closest
genes. For somatic indels, 13 (0.28%) indels were in the coding region,
5 were in the exonic region of noncoding RNA, and 2 in introns were
overlapping with a splicing site.
Intragenic Mutations
Besides the mutations in coding regions, many mutations in intro-
nic or gene flanking regions may potentially affect gene expression or
regulation and thus may have functional consequences [14,15]. To
characterize such likely functional somatic mutations, we grouped
the somatic mutations by genes. There are a total of 27,925 genes
of nonidentical genomic positions in RefSeq hg19 [as assembled
by ANNOVAR, June 2012 [10]]. Within 1 kb downstream or
upstream of each gene, we found SPMs and somatic indels in
2729 genes among 10 tumor samples. Given that detected SPMs
Table 2. Validation Results of Somatic Mutations.
SPMs Somatic Indels
No. Validated (Total) Validation Rate* No. Validated (Total) Validation Rate*
T1 2747 (3228) 0.85 2248 (3085) 0.73
T2 3028 (3696) 0.82 2356 (3279) 0.72
T3 3402 (4043) 0.84 2256 (3202) 0.7
M1 3532 (4102) 0.86 2166 (3254) 0.67
M2 3476 (3932) 0.88 2219 (3028) 0.73
Overall† 5236 (5701) 0.92‡ 3368 (4347) 0.77‡
*Validation rate for T1 to M2 shows the proportion of variants in a batch “a” sample that were
validated in the corresponding batch “b” sample.
†Overall shows the number of variants validated (identified) in at least one of the five tumor sam-
ples (T1, T2, T3, M1, or M2).
‡Overall validation rate shows the proportion of variants identified in at least one tumor sample in
batch “a” that were validated in at least one tumor sample in batch “b.”
Table 1. Sequencing Statistics.
Batch a T1a T2a T3a M1a M2a Na
At Known Sites
Total bases mapped 120.8 135.6 130.1 137.2 123.3 119.1
Mean depth 42.3 47.5 45.5 48.0 43.1 41.7
Coverage (%) 97.93 97.93 97.9 97.91 97.89 97.96
No. of SNPs Detected (Q ≥ 20)
SNPs 3,690,282 3,680,844 3,678,250 3,679,869 3,648,729 3,691,527
Transition/transversion 2.06 2.06 2.06 2.06 2.06 2.06
Heterogeneous/homogeneous 1.5 1.48 1.48 1.48 1.46 1.49
Concordance with Quad SNPs (%) 99.89 99.85 99.83 99.74 99.63 99.89
In dbSNP (%) 93.8 93.7 93.8 94 93.9 93.9
No. of Indels Detected (Q ≥ 20, length ≤ 300)
Insertions 311,033 309,245 305,466 318,674 293,919 315,539
Deletions 329,908 329,198 327,838 338,497 316,097 331,755
Breakpoints 26,636 26,536 25,823 28,802 24,867 27,365
Batch b T1b T2b T3b M1b M2b Nb
At Known Sites
Total bases mapped 110.3 112.5 100.7 102.3 106.3 99.8
Mean depth 38.6 39.3 35.2 35.8 37.2 34.9
Coverage (%) 97.9 97.95 97.84 97.92 97.92 97.85
No. of SNPs Detected (Q ≥ 20)
SNPs 3,655,604 3,659,173 3,658,838 3,616,641 3,621,011 3,661,077
Transition/transversion 2.06 2.05 2.06 2.06 2.06 2.06
Heterogeneous/homogeneous 1.48 1.47 1.48 1.46 1.45 1.48
Concordance with Quad SNPs (%) 99.28 99.27 99.28 99.27 99.25 99.26
In dbSNP (%) 93.8 93.7 93.8 94 93.9 93.9
No. of Indels Detected (Q ≥ 20, length ≤ 300)
Insertions 295,118 306,338 293,880 280,595 285,086 295,240
Deletions 313,896 321,806 311,007 301,312 304,709 312,708
Breakpoints 9,605 9,860 9,073 8,447 9,062 9,224
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had much higher validation rate than somatic indels, we compared
the heterogeneity of somatic mutations among tumors on the basis of
genes containing SPMs. In particular, for the five tumor samples in
the discovery set, there were 1805 genes with SPMs. Among these
genes, 1029 were shared among all five samples, whereas T1a,
T2a, T3a, M1a, and M2a contained 57, 50, 149, 37, and 29 unique
genes with SPMs that were not shared by any other tumors (see
Venn diagram in Figure 2). Among genes with SPMs that were
shared between several but not all tumors, the largest group was the
169 genes shared by all four tumors except for T1a, followed by the
99 genes shared only between the two metastatic samples. This likely
indicated a closer evolutionary relationship among these samples.
Among all functional genes, there are 488 genes classified as
cancer-associated genes by the Cancer Genome Project (Wellcome
Trust Sanger Institute). Of these cancer genes, there are 428 unique
geneIDs on autosomes. We identified their locations using their
Entrez ID in Ensembl genome database (The EMBL-European
Bioinformatics Institute) or NCBI Gene (NCBI). In total, we found
162 somatic mutations (SPMs or somatic indels) located within 1 kb
of 71 cancer genes. Of these, 55 cancer genes contained somatic mu-
tations that were validated by the corresponding sample in batch “b”
(Table W2; for a list of contained mutations, see Table W3). Similar
Table 3. Annotations of Somatic Mutations.
Total Subcategories SPMs Somatic
Indels
6440 % 4638 %
Intragenic 2017 31.32 1550 33.42
Coding 61 0.95 13 0.28
Nonsynonymous 41
Synonymous 16
Stop-gain 1
Unknown 3
Noncoding, transcribed 247 3.84 164 3.54
ncRNA (exonic) 17 5
ncRNA (intronic) 188 125
UTR3 35 31
UTR5 7 3
Intronic 1632 25.34 1313 28.31
Splicing 1 2
Other 1631 1311
Flanking 77 1.20 60 1.29
Downstream (1 kb) 38 26
Upstream (1 kb) 39 34
Intergenic 4423 68.68 3088 66.58
ncRNA indicates noncoding RNA; UTR3/UTR5, untranslated region 3/5.
Figure 1. Distribution of transition and transversion types of SPMs over the entire genome (A) and in the protein-coding region of the
genome (B).
Figure 2. Venn diagram plot shows number of shared and unique
genes with identified SPMs among batch “a” samples.
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to the entire set of functional genes, the majority (34 of 55) of cancer
genes were shared by all the five samples in batch “a.” This probably
indicates the possible common root of all these tumors. Two genes
previously implicated in squamous cell carcinomas, specifically notch
(Drosophila) homolog 2 (NOTCH2) and epidermal growth factor
receptor (EGFR) [16–18], both contained intronic mutations in all
tumor samples. However, mutations in five cancer genes [K(lysine)
acetyltransferase 6A (KAT6A), PR domain containing 16 (PRDM16),
mastermind-like 2 (Drosophila) (MAML2), zinc finger and BTB
domain containing 16 (ZBTB16), and B-cell CLL/lymphoma 10
(BCL10)] had mutations only in three primary tumor samples (T3,
T2, T2, T1, and T1, respectively), and four cancer genes [c-abl
oncogene 2, nonreceptor tyrosine kinase (ABL2), pre-B-cell leukemia
homeobox 1 (PBX1), SET domain containing 2 (SETD2), and tri-
partite motif containing 24 (TRIM24)] had mutations only in the
two metastatic samples. Ingenuity Pathway Analysis (version 16542223;
Ingenuity Systems; http://www.ingenuity.com) was applied to these
genes to determine pathways potentially affected by these mutations
(Table 4). Genes with mutations in primary tumor samples only were
significantly associated with Notch signaling, transcriptional regulation
in embryonic stem cells, high mobility group-B1 (HMGB1) signaling,
and multiple pathways involving signaling in lymphocytes. Those genes
with mutations in the lymph node samples only were significantly
associatedwith transcriptional regulation in embryonic stem cells, PDGF
signaling, Ras homolog gene family, member A signaling, and retinoic acid
receptor activation.
Cancer Genome Evolution
Following the clonal expansion hypothesis, we expected that
multiple clones were present within a single tumor but in different
physical locations of the primary and metastatic tumors. Dissecting
heterogeneities across their sequences allowed us to capture the evo-
lutionary relationship among these 10 tumor samples. A coalescent
tree (Figure 3) was built for the 10 tumor samples together with the
sample from peripheral blood (“N”) on the basis of their shared
cancer-associated genes containing SPMs. It appeared that tumor
samples physically close to each other were more homogeneous
and were clustered to the same branch. The primary tumors at the
first site (T1a and T1b) were closer to the founder clone, whereas
those at the second and the third sites contained additional muta-
tions and occurred in more distant branches. All four metastatic sam-
ples were clustered in the same branch and appeared to have evolved
from the same parental clone. Bootstrap and jackknife sampling were
done to evaluate the significance of the coalescent tree, and the struc-
ture was found to be consistent throughout (data not shown).
We estimated that the tumor in this patient took approximately
8.7 years to develop an initial tumor clone from one or more single
somatic mutations. From this initial clone, it took approximately
another 6.6 years for the single clone to evolve into the six primary
tumor cell populations that have been observed. It took another
2 years for one of the clones to establish four tumor cell populations
present in the metastatic lymph node.
Discussion
By sequencing whole genomes on multiple cancerous cells extracted
from different portions of the primary tumor and also from two dif-
ferent metastatic sites on a single patient with OSCC, we were able to
Table 4. Cancer Genes with Mutations in Primary Tumor and Lymph Node Samples.
Pathway P Value Genes
Genes Mutated in Primary Tumor Samples Only
Notch signaling .011 MAML2
Transcriptional regulatory network in embryonic stem cells .012 MYST3
Regulation of IL-2 expression in T lymphocytes .024 BCL10
HMGB1 signaling .028 MYST3
T cell receptor signaling .029 BCL10
Cluster of differentiation 28 signaling in T helper cells .034 BCL10
Protein kinase C θ signaling in T lymphocytes .034 BCL10
Phosphoinositide 3-kinase signaling in B lymphocytes .038 BCL10
B cell receptor signaling .047 BCL10
Nuclear factor kappa-light-chain-enhancer of activated B cells signaling .049 BCL10
Genes Mutated in Lymph Node Samples Only
Transcriptional regulatory network in embryonic stem cells .009 TRIM24
PDGF signaling .018 ABL2
Ras homolog gene family, member A signaling .028 ABL2
Retinoic acid receptor activation .041 TRIM24
Figure 3. (A) Coalescent tree is based on number of shared genes containing SPMs. (B) Timeline of tumor progression based on
estimated mutation rate indicates significant passage of time from the development of the initial cancerous cell to the development
of the parental clone of all tumor samples obtained.
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characterize the extent of small somatic mutations (SPMs and small
indels) on the genome-wide scale, examine the tumor heterogeneity
among different tumor sites, and also investigate the pattern of tumor
evolution from initiation to metastasis. This is the first such study in
HNSCC to examine intratumor heterogeneity by performing whole-
genome sequencing in multiple tumor samples from a single patient.
Although one previous study performed whole-genome sequencing on
an HPV-negative oropharyngeal tumor and an HPV-negative hypo-
pharyngeal tumor [[5]], the current study is the first to perform
whole-genome sequencing on an HPV-positive HNSCC. This study
provides a model that can be applied to the investigation of
additional HNSCC tumors to determine shared and unique patterns
of mutation and clonal evolutionary breakpoints.
Overall, this HPV+ tumor had 6440 SPMs and 4638 small indels
based on the discovery set with an overall validation rate of 92% and
77%, respectively. Thus, despite the potentially higher detection sen-
sitivity by the revised chemistry of the Illumina sequencer, the higher
sequence coverage still seems to increase the sensitivity of mutation
detection. Our validation samples were sequenced at approximately
37× coverage compared to approximately 45× coverage in the discov-
ery set. Around 0.9% fewer SNPs and 5% fewer small indels were
detected in the validation set. The much lower detection rate of
indels in the validation set could be due to the difficulty of aligning
reads with indels, which also partially explained the lower validation
rate for small indels. Although indels may have significant impacts on
cellular phenotype, we restricted further analysis to the SPMs due to
their higher validation rates.
The greater frequency of mutations found in this study compared
with those found by Stransky et al. and Agrawal et al. [5,6] in HPV+
tumors is likely due to the fact that we report mutations on the whole
genome as opposed to focusing on the exome as was done in these
two studies. In fact, the majority of the mutations we found were in
noncoding regions, which would not have been detected by exome
sequencing alone. In accordance with these two studies, only 61 SPMs
were located within exons of protein-coding genes. Several tumor
suppressors and oncogenes have been previously implicated in HNSCC
including tumor protein p53 (TP53), cyclin-dependent kinase inhibitor
2A (CDKN2A), TP63, phosphatase and tensin homolog (PTEN),
NOTCH1, NOTCH2, NOTCH3, F-box and WD repeat domain con-
taining 7, E3 ubiquitin protein ligase (FBXW7 ), phosphatidylinositol-4,
5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA), cyclin D1
(CCND1), HRAS, and EGFR [5,6,18]. In our study, none of these
genes had exonic mutations in any tumor sample. Two of these genes,
NOTCH2 and EGFR, both contained intronic mutations that were
present in all tumor samples we assessed. Our exclusion of known SNPs
identified in the 1000 Genomes Project and dbSNP databases poten-
tially excluded SPMs that coincided with known SNPs. As suggested
in previous studies [5,6], HPV-positive tumors, such as the one we
examined, may be expected to have fewer mutations compared to other
tumors, particularly those associated with heavy exposure to tobacco
and alcohol. The major risk factors for HNSCC include tobacco use,
alcohol abuse, and infection with high-risk HPV strains [18]. Tobacco
and alcohol are thought to contribute to tumor pathogenicity by induc-
ing DNA mutations [19]. Although high-risk HPV strains likely cause
tumor pathogenicity through functional inactivation of p53, genomic
instability may still occur during clonal expansion of tumor cells and
result in intratumor heterogeneity. Amore widespread analysis is needed
to clarify which mutations in tumor suppressors and oncogenes are
involved in HPV-positive and HPV-negative tumors and which may
be important in the development and testing of therapeutic agents tar-
geting the pathways associated with these genes. It is likely that targeted
pathways may be different depending on HPV status.
Interestingly, despite detection of HPV E6 sequences by PCR and
uniformly positive p16 staining by IHC, we did not observe HPV inte-
gration in our data by WGS, nor could we map short-read sequences
to the HPV reference genome. The following reasons for this could
be multifactorial: insufficient depth of sequencing, algorithm/software
difficulty of aligning short reads at insertion sites, HPV sequence varia-
tions from reference, and other factors. In the future, more sensitive
sequencing tools might allow detection of HPV genome integration
and localization of insertion site(s).
In earlier studies of HNSCC somatic mutations, a common study
design is to compare genetic profiles between a single tumor sample
and a single normal sample, e.g., adjacent normal tissue or blood
from the same patient [5,6,20,21]. Although these studies have pro-
vided important insight into cancer genomic instability, they cannot
easily provide insight into tumor heterogeneity without making
unsubstantiated assumptions [22]. If single tumor biopsies are used
to identify molecular biomarkers for guiding therapy without fully
documenting intratumor heterogeneity and identifying essential
somatic mutations, one may be misled, hence, subject patients to
unnecessary risk or inadequate treatment. In the current feasibility
study, we demonstrated that, although a slight majority of genes with
SPMs were shared by all five tumor samples, only 41% SPMs and
46% of somatic indels were shared by all.
The degree of intratumor heterogeneity detected in this tumor
permitted us to estimate the branching process of clonal expansion
and to approximate the timeline of tumor development by phylo-
genetic construction. It was shown that the physically adjacent tumor
samples (in batch “a” and batch “b”) were placed in the same branch
of the phylogenetic tree, as might be expected from the clonal expan-
sion process. This branching type of evolution has been observed in
several other cancer types as well [1]. It is a commonly held belief
that the majority of solid tumors originate from a single cell that
develops the potential for unregulated growth and, eventually, inva-
sive and metastatic potential. Our results here support a branching
evolutionary process that can be traced backward to a common pro-
genitor clone, and they suggest a significant amount of time during
which it may be possible to detect tumors at early stages. By estimat-
ing the sequence of genetic mutations that occur during clonal
expansion, this approach may help to identify driver mutations con-
tributing to early tumor growth, which can then be targeted with
selective therapies.
Currently, the single greatest prognostic factor in HNSCC is the
presence or absence of cervical lymph node metastases, which are
associated with approximately 50% reduced survival [23]. By estab-
lishing genetic mutations unique to metastatic clones, targeted ther-
apies may be developed with improved efficacy against disseminated
disease. Our results suggest that the two metastatic samples had a
high degree of similarity. The estimated timeline of tumor develop-
ment placed the metastatic samples at a later time than the develop-
ment of the primary tumor samples. The two metastatic samples
shared a total of 99 intragenic mutations that were not present in
any primary tumor sample, and the metastatic samples then had
an additional 29 and 37 unique mutations, respectively. Those
mutations that are shared by both lymph node samples but not pres-
ent in the primary tumor may confer metastatic ability. Four pro-
posed cancer genes had intronic mutations that were present in the
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metastatic samples only. One of these, ABL2, has recently been
shown to function downstream of the EGFR and contribute to tumor
cell invasion and blood vessel intravasation [24]. A recent study
showed an inverse relationship between expression of TRIM24, a
protein thought to interact between chromatin and several nuclear
receptors, in HNSCC tumors and patient survival and that knock-
down of TRIM24 in HNSCC cell lines inhibited cell growth [25].
It is unknown whether the intronic mutations we identified in the
metastatic samples of our patient have any effect on protein expression
or function, however.
In this study, we studied the tumor heterogeneity and tumor clonal
expansion in OSCC on the basis of SPMs and small indels. Larger
mutations such as loss of heterozygosity, copy number variation, and
translocations were not exploited. It is expected that larger mutations
may exhibit larger phenotypic effects. However, a systematic examina-
tion of such mutations remains to be done. Additionally, the majority
of mutations, including those within cancer genes, were observed
within introns or intergenic segments. The impact of mutations within
these regions on gene expression has become increasingly accepted.
Future studies to determine how intratumor heterogeneity affects gene
expression will help to elucidate biologically relevant genomic alter-
ations. Our data support the presence of significant intratumor hetero-
geneity, and larger studies with more patients and larger number of
tumor samples are warranted to further determine the degree of intra-
tumor heterogeneity in HNSCC tumors. Larger studies will be valuable
to identify any common mutations and any common clonal branch-
ing points.
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Supplemental Methods
Somatic Mutation Detection
To reduce false-positive discoveries of somatic mutations, we applied
a set of stringent and relatively conservative criteria on the basis of
quality scores of individual reads, read depth, and variant calling con-
fidence. Firstly, mutation sites were filtered to be those sites of high
confidence in the tumor specimen. For SNPs in each tumor DNA,
we required the phred-based quality Q(SNP) [1] to be at least 40, at
least 20 reads coving the site (read depth), unique alternative allele,
and at least 20% of alternative alleles among all reads. For indels, we
required Q(indels) ≥ 40, read depth ≥ 40, at least 10 reads of indel
calls, and at least 10 reads of reference allele calls for heterozygous indel
sites. Secondly, the mutation sites were further filtered to be those of
low mutation possibility in the blood samples. In both Na and Nb, for
SNPs, we required that Q(SNP) = 0, a read depth of at least 20, and at
least 80% of reference alleles; whereas for indels, we required Q(indels)
< 3, a read depth of at least 20, and no indel calls. Thirdly, using
ANNOVAR [2], we excluded the mutations that have been identified
in public databases, including dbSNP (version 132) and the 1000
Genomes Project [3] (Phase 1, March 2012 release). Lastly, to mini-
mize the technical differences (such as random read sampling or tumor
tissue dissections) among these tumor specimens of the same indi-
vidual, we re-examined the possibilities of mutations in each tumor
DNA, at the somatic mutation sites that have been identified with high
confidence in at least one tumor DNA. We rescued a number of such
mutations using relaxed conditional quality score criteria as Q(SNP|
polysite)≥ 20 or Q(indel|polysite)≥ 20, instead of Q(SNP) or Q(indel)
score. In the end, a set of high-confidence somatic mutations was
obtained for each tumor sample.
Estimation of Chronological Time of Tumor Evolution
Following exactly as [4], the accumulation of N somatic muta-
tions was modeled as a Poisson process, where the number of cell
divisions C i to obtain the ith mutation follows an exponential dis-
tribution with rate r. If assuming a mutation rate per base pair per
cell generation is 5 × 10−10 [4] and the length of human genome is
approximately 3 × 109 bp, then r, the number of mutations per cell
generation, would be 1.5. Assuming each new somatic mutation occurs
independently, the total number of cell generations to accumulate
N mutations would be the summation of all C i, which have a
Gamma distribution with mean N /r and SD
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
N = r
p
. Thus,
C = ∑Ni=1Ci∼Gamma N ;
1
r
 
.
Given that the average cell doubling time (cell generation T gen)
in oral cancer is not currently known, we used the estimation of
2.3 days in pancreatic cancer [4] and estimated the time to accumu-
late N somatic mutations as
T =
Tgen
r
N 
ﬃﬃﬃﬃ
N
p 
:
The tumor evolution was divided into the following three phases:
P1, from tumor initialization to the parental clone; P2, from the
parental clone to subclones; and P3, to develop metastasis after
subclones. The evolutional time for each phase was estimated using
the above formula with N 1, N 2, and N 3 as the corresponding
number of somatic mutations. We estimated N 1 as the number of
somatic mutations shared in all 10 tumor samples. Then, N 2 was
calculated as the average number of mutations in each primary tumor
but not in the parental clone. Similarly, N 3 was calculated as the
average number of mutations in each metastasis but neither in the
primary tumor nor in the parental clone.
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Figure W1. Number of somatic point mutations (A) and somatic indels (B) in sliding windows of size 500 kb between batch “a” and “b”
samples. The x-axes are for the batch “a” samples, and the y-axes are for the batch “b” samples.
